Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02669017 · ClinicalTrials.gov registry record · Phase 1
Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)
A Phase 1 study, sponsored by ADC Therapeutics S.A..
- Completed
- Registry status
- Phase 1
- Development phase
- 183
- Enrollment target
NCT02669017 is a Phase 1 study that has completed, run by ADC Therapeutics S.A.. The registered enrollment target is 183 participants.
The verdict
NCT02669017, a Phase 1 study, has completed, sponsored by ADC Therapeutics S.A..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 183 participants
- Enrollment target
Study Summary
This study evaluates ADCT-402 in participants with Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL). Participants will participate in a dose escalation phase (Part 1) and dose expansion (Part 2). In Part 2, participants will receive the dose level identified in Part 1.
Interventions
- DRUG ADCT-402
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 183 participants |
| Start Date | 2016-03 |
| Est. Completion | 2019-02-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02669017
The ClinicalTrials.gov registry entry for NCT02669017 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 183 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ADC Therapeutics S.A., which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ADCT-402 is the first listed.
NCT02669017 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02669017 about?
NCT02669017 is a clinical study titled "Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)". This study evaluates ADCT-402 in participants with Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL). Participants will participate in a dose escalation phase (Part 1) and dose expansion (Part 2). In Part 2, participants will receive the dose level identified in Part 1.
What is the current status of trial NCT02669017?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 183 participants. The study started on 2016-03. Estimated completion is 2019-02-21.
What interventions are being tested in trial NCT02669017?
The interventions under investigation include: ADCT-402 (DRUG).
Who is sponsoring clinical trial NCT02669017?
This trial is sponsored by ADC Therapeutics S.A., which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.